SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility and trending status driven by intense speculation around a potential short squeeze, with community members highlighting an increasing cost-to-borrow rate and low share availability. Investors are closely monitoring the upcoming earnings report, viewing it as a critical catalyst while debating the company's valuation and the effectiveness of its growth strategy compared to broader AI sector trends.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing intense volatility as the community speculates on technical breakouts and potential short-squeeze activity fueled by social media buzz. Investors remain divided, with some betting on a rapid move upward based on technical patterns, while others express frustration over the stock's persistent sideways movement and lack of major corporate news.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending as traders speculate on potential price appreciation, driven by a recent licensing agreement and anticipation of clinical data presentations. While some community members are focused on a possible short squeeze and technical breakouts, others remain cautious, citing risks associated with the company's capital structure and previous stock performance.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors react to a significant expansion of its AI infrastructure partnership with Yotta, valued at approximately $2.8 billion and bolstered by NVIDIA's involvement. The community is actively discussing the stock's massive long-term potential, with bulls pointing to the heavy short interest and tight share float as catalysts for a potential squeeze, while some remain cautious about management's guidance and execution timelines.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating intense community interest driven by micro-float momentum and speculative trading dynamics often seen in low-float, high-volatility setups. Traders are actively debating the sustainability of the stock's recent price action, with some highlighting potential for short squeezes while others warn of risks related to debt and dilution.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares are under significant downward pressure following a guidance cut that cited user growth friction caused by new age-verification and safety measures. While some community members view the dip as an oversold buying opportunity, others are heavily focused on the company's lack of profitability and the broader debate surrounding platform safety.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense momentum as the community monitors its aggressive expansion plans, including a significant footprint increase in Houston to meet massive demand for 800G and 1.6T transceivers. While bullish investors view this scaling as proof of institutional demand and a clear supply chain advantage, bears are highlighting concerns regarding the company's valuation, history of losses, and potential insider selling.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors react to the company's decision to maintain its full-year guidance despite reporting record loan originations and consistent member growth. While the community remains deeply divided between those viewing the pullback as an attractive long-term buying opportunity and others frustrated by ongoing share dilution and inconsistent stock performance, many are actively monitoring the stock's ability to hold critical support levels.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail interest and positive price momentum as investors speculate on the potential for its proprietary electro-optic polymer technology to become a critical component in next-generation AI and high-speed data center infrastructure. The community is actively debating the company's path toward commercialization and watching for potential institutional partnerships or licensing deals that could validate its long-term growth potential.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened volatility and intense retail debate as the market anticipates quarterly results, with community discourse centered on the company's capital burn, potential dilution, and the critical R2 SUV launch. Traders are actively weighing strong delivery growth and strategic partnerships against macro headwinds like European tariffs and the company's long-term path to profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat...

Tenaya Therapeutics (NASDAQ:TNYA)  Shares Down 5%   - Here's What Happened

Tenaya Therapeutics (NASDAQ:TNYA) Shares Down 5% - What's Next...

Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Chardan Capital reiterated a "buy" rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday...

Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates...

Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy

Lifesci Capital raised shares of Tenaya Therapeutics to a "strong-buy" rating in a report on Thursday...

<ul class="summary-bullets"><li>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam.</li><li>Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.</li></ul> Shares of Tenaya Therapeutics, Inc. (TNYA) pulled back after hours after a significant rally during the regular session on Thursday after the company said that it has entered into a research collaboration deal with Alnylam Pharmaceuticals (ALNY) to potentially develop drugs for cardiovascular disease.TNYA shares pulled back 5% in extended hours of trading after closing up 41% in the regular session.<h2 class="st-heading-2">Deal For Heart Drugs</h2>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam if all the targets lead to approved therapies for cardiovascular disease. Tenaya will receive up to $10 million in the form of an upfront payment, the company said.“By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease,” Tenaya CEO Faraz Ali said.Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNYA stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said that they are awaiting positive data for Tenaya’s TN401 this year with “no curative competition.” TN-401 is a gene therapy for a heart condition called PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).<stembedurl>https://www.stocktwits.com/Raumerica/message/646689743</stembedurl>Another said that the best part about the deal is that Tenaya will just be researching fifteen additional targets for future commercialisation while still owning all of its own drugs.<stembedurl>https://www.stocktwits.com/Raumerica/message/646703938</stembedurl><a href="https://stocktwits.com/symbol/TNYA">TNYA stock</a> has gained 78% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/owlet-stock-is-down-26-percent-after-hours-after-it-reports-q4-2025-earnings/cZdX4n1RI36">Owlet Stock Is Down 26% After Hours – How Did The Company’s Q4 Results Fare?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 

Equity

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 


Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.read more...

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 658,440 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction on Tuesday, February 24th. The stock was...

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

Current Price	$0.7001
Prev Close	$0.6911
Open	$0.6931
Dividend Yield	0.00%
50-Day Moving Average	$0.7194
Beta	2.36
Avg. Volume	5.65M
PE Ratio	-1.10

52-Week High	$2.35
52-Week Low	$0.36
Market Capitalization	$149.97M
EPS (Annual)	-$0.5923
Price to Book	1.22
Revenue Per Employee	$0.00

TNYA
Tenaya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNYA News

TNYATenaya Therapeutics Inc